Physician profile
Xin Wang
NPI 1083450407
$5,078.26
in general payments reported to CMS, 2019-2025
23 companies · $4,401 in 2025
The $4,401 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $677 · 2025: $4,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,892 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,892.28 |
| Education | $185.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.62 | 2024-2025 | |
| Galderma Laboratories, L.P. | $483.66 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $470.98 | 2024-2025 | |
| Janssen Biotech, INC. | $423.69 | 2024-2025 | Tremfya |
| Incyte Corporation | $407.56 | 2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $387.30 | 2025 | |
| Ucb, INC. | $364.43 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $336.12 | 2024-2025 | Dupixent, Libtayo |
| Organon LLC | $193.55 | 2025 | Vtama |
| Dermavant Sciences, INC. | $179.57 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.94 | 2025 | Spevigo |
| Leo Pharma INC. | $159.93 | 2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $155.54 | 2025 | Zoryve |
| Journey Medical Corporation | $150.39 | 2025 | |
| Janssen Scientific Affairs, LLC | $114.87 | 2024 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $99.47 | 2024-2025 | Dupixent |
| Amgen INC. | $83.28 | 2025 | Otezla |
| Pfizer INC. | $77.63 | 2025 | |
| Lilly USA, LLC | $67.43 | 2024-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $47.57 | 2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $44.05 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $16.06 | 2025 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.62 | 2024 | Duobrii, Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.